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ttp://dx.doi.org/10.1016/j.ajpath.2012.10.006Chronic inﬂammation driven by immune responses to lipid deposition in the arterial wall is now
understood to be fundamental to the pathogenesis of atherosclerosis. The frequent presence of T
lymphocytes in human atherosclerotic lesions was ﬁrst described in the 1980s, but experiments to test
whether adaptive immunity inﬂuences lesion development and phenotype required animal models. The
American Journal of Pathology has published many research articles focused on the role of inﬂammation
and adaptive immunity in diet-induced and genetically manipulated murine models of atherosclerosis.
Seminal articles in the 1990s were the ﬁrst to describe the presence of T cells in mouse atherosclerotic
lesions; other articles demonstrated the effects of defective adaptive immunity on lesion development
in mice. (Am J Pathol 2013, 182: 5e9; http://dx.doi.org/10.1016/j.ajpath.2012.10.006)Supported by NIH grant R01-HL087282.The pathogenesis of atherosclerosis involves chronic
inﬂammatory responses to lipoproteins deposited in the
arterial intima. The essential importance of inﬂammation to
this disease is clearly evident from analyses of human and
animal lesions, and from experimental manipulation of
animal models. A previous review in The American Journal
of Pathology (AJP) discusses the possible causes and
consequences of inﬂammation in the context of athero-
sclerosis.1 In the 1980s, Goran Hansson and colleagues2,3
ﬁrst described the regular presence of activated T lympho-
cytes in human atherosclerotic plaques, and similar ﬁndings
were reported by Emeson and Robertson.4 These studies
were among the ﬁrst to indicate that adaptive immune
responses could be involved in the pathogenesis of athero-
sclerotic lesions. At that time, inbred strains of mice had
already been established as essential tools for immunology
research, and so the potential usefulness of mice to exper-
imentally examine the inﬂuences of the immune system on
atherosclerosis was an obvious consideration after the
provocative, albeit descriptive studies implicating T cells in
human arterial disease. Seminal studies that focused on
immune modulation of atherosclerosis in mice, some of
which were published in the AJP, represent the dawn of
a highly productive era of mouse-based research in
cardiovascular immunology. This review discusses progress
in our understanding of the inﬂuences of adaptive immunitystigative Pathology.
.in atherosclerosis, with a focus on T cells, as reﬂected by
AJP articles over three decades.Seminal Studies with C57BL/6 Mice in the AJP
Before robust genetically manipulated mouse models of
atherosclerosis became widely available, investigators
studied this disease in C57BL/6 mice a fed high-fat,
cholesterol-rich diet containing cholic acid (known as the
Paigen diet), which reliably induced lipid-rich, fatty streak
lesions in the aortic root.5 In the ﬁrst study attempting to
determine how T cells inﬂuence atherosclerosis, Emeson
and Shen6 examined the effects of cyclosporin treatment on
lesion development in C57BL/6 mice fed a Paigen diet and
reported their ﬁndings in the AJP. Contrary to expectations,
the mice receiving the calcineurin inhibitor developed bigger
lesions. That study failed to determine whether T cells had
direct effects on lesion development because the drug treat-
ment resulted in markedly elevated blood levels of total and
low-density lipoprotein cholesterol, reﬂecting the effects of
calcineurin inhibitors on several cell types. Although in that
study the authors did not clarify how adaptive immunity
contributes to atherosclerotic disease, they did establish the
Lichtmangeneral approach of monitoring lesion development in mice
after pharmacological immune intervention. Importantly, the
article highlighted the need to rule out effects of the inter-
ventions (pharmacological or genetic) on lipid metabolism
before making conclusions about direct effects of immune
responses on lesion development.
Three years later, Emeson et al7 published a second study in
the AJP, in which they examined the inﬂuence of T-cell
deﬁciency on aortic root lesion development in cholesterol/
cholic-acidefed mice. In that study, the investigators fed an
atherogenic diet to T-celledeﬁcient nu/nu or control nu/þ
mice for approximately 31 weeks. They reported a marked
reduction in aortic root lesion size in the T-celledeﬁcient
group. At that time in the 1990s, there were general concerns
in the ﬁeld about the relevance of lesion development in the
cholic-acidefed C57BL/6 mouse model, because of systemic
and hepatic inﬂammatory effects of the diet and because of the
lack of development of mature lesions with smooth muscle
cells and ﬁbrosis. In retrospect, however, the results actually
portended the similar ﬁndings that would be seen with global
adaptive immune deﬁciency in mouse atherosclerosis models
that do not require cholic acid. Emeson et al7 also found that
depletion of CD4þ cells usingmonoclonal antibodies reduced
aortic lesion size by approximately 70%. This result was also
predictive of later studies demonstrating proatherogenic
effects of CD4þ T cells, using mice genetically susceptible to
atherosclerosis.8,9Adaptive Immunity and Genetically
Hypercholesterolemic Apoe/ and
Ldlr/ Mice
In the early 1990s, the Apoe/ and Ldlr/ mouse strains
were derived by homologous recombination-mediated gene
deletion; these animals develop severe hypercholesterolemia
and atherosclerotic lesions with features of mature human
lesions.10e13 Over the past 20 years, these mouse strains have
been widely distributed and extensively used to study many
aspects of dyslipidemia and atherosclerosis. In one of the ﬁrst
reports of using such mice to study adaptive immunity in
atherosclerosis, Hansson and colleagues8 identiﬁed CD4þ T
lymphocytes in early and advanced lesions of Apoe/ mice
fed either a standard or cholesterol/high fat diet. The T cells
were found to express the activation marker CD25.8 The
authors also found abundant class II MHC expression in the
lesions, suggesting local immune activation and indicating
that antigen presentation to CD4þ T cells within plaques is
possible. This article, published in the same issue of the AJP
as the above-mentioned study of Emeson et al,7 was important
because it showed similarities in the immune phenotype of
lesions in the Apoe/model and human lesions. In the same
month, the presence of T cells in lesions of both Ldlr/ and
Apoe/ mice was also reported by Daugherty and
colleagues.14 The knowledge that atherosclerotic lesions in
thesemouse strains, likehuman lesions, contain the cellular and6molecular signature of the effector phases of T-cellemediated
immune responses was key for stimulating future investigative
work on the mechanisms and effects of these responses.15
In another early study published in the AJP addressing the
inﬂuence of adaptive immune responses to atherosclerosis,
Robert Colvin and colleagues16 transplanted hearts from
donor mice of the 129 strain into Apoe/ C57BL/6 or
control C57BL/6 mice. They observed that in the hyper-
lipidemic Apoe/ recipients, lipid-rich aortic and coronary
atherosclerotic lesions in the transplanted hearts were more
severe than in the native hearts, with more inﬁltrating
lymphocytes, indicating that T-cellemediated alloreactivity
enhanced atherosclerosis.The Effects of Immunodeﬁciency on
Atherosclerosis in Apoe/ and Ldlr/ Mice
The development of the robust Apoe/ and Ldlr/ mouse
models permitted investigators to test the effects of different
components of the immune system by crossbreeding these
mice with other strains carrying null mutations in immuno-
logically relevant genes. Some of the ﬁrst studies taking this
approach addressed the question of the effect of global loss of
the entire adaptive immune system.Rag1/ orRag2/mice
lack the V(D)J recombinase required to form lymphocyte
antigen receptor genes. Therefore, Rag1/ or Rag2/mice
have a complete absence of B and T cells; that is, they have no
adaptive immune system. SCID mice carry mutations in
a gene encoding a DNA repair enzyme that is needed for
antigen receptor gene formation, and these mice have
a severe, albeit not complete, lack of T and B cells. When
Apoe/ mice were fed a high-fat, high-cholesterol diet,
resulting in high plasma cholesterol concentrations (w1000
mg/dL), there was little effect of RAG deﬁciency (ie,
lymphocyte deﬁciency).17,18 In Apoe/ mice fed a regular
chow diet, however, with plasma cholesterol concentrations
of approximately 390 to 470 mg/dL, lymphocyte deﬁciency
resulted in a 40% reduction in lesion formation.17 Apoe/
SCIDmice fed a regular chow diet showed a 73% reduction in
aortic lesions, compared with immunocompetent Apoe/
mice fed the same diet; plasma cholesterol content in both
groups was approximately 470 mg/dL.19 RAG-deﬁciency in
atherogenic diet fed Ldlr/ mice resulted in signiﬁcantly
reduced early lesion development compared to immuno-
competentLdlr/mice.20 The serum cholesterol levels in the
Ldlr/mice in that study were approximately half the levels
usually attained in similarly fed Apoe/ mice.
Overall, studies with mice lacking an adaptive immune
system suggest a signiﬁcant proatherogenic role for the
adaptive immune system; moreover, the effect can be
obscured when hypercholesterolemia is severe. Given that
one central ultimate effector of adaptive immunity is the
activated macrophage, and macrophages can be activated in
the absence of T cells or antibodies by innate stimuli gener-
ated by oxidative degradation of low-density lipoprotein, itajp.amjpathol.org - The American Journal of Pathology
ASIP Centennial Reviewis not surprising that the inﬂuence of the adaptive immune
system on atherosclerosis is not apparent under extreme
hypercholesterolemic conditions.
Comparison of atherosclerotic lesion development
between atherosclerotic-prone (Apoe/ or Ldlr/) mice
with or without homozygous null mutations of Rag or Scid
genes may seem like a straightforward way to determine
whether adaptive immunity does or does not inﬂuence
atherosclerosis. However, atherosclerosis and the immune
system are too complex for such a simple approach to
always yield readily interpretable information. In fact, the
net effect of the global loss of all components of the adaptive
immune system on atherosclerotic disease in these mouse
models will reﬂect both a loss of proinﬂammatory effector
functions (T cells, B cells, and antibodies) and a loss of
regulatory functions of T and B cells that affect endothelium
and innate immune system cells. There is also solid evidence
for direct atheroprotective effects of some, but not all,
antibodies induced under hypercholesterolemic condi-
tions.21 Thus, more selective manipulations of distinct
components of the adaptive immune system are necessary
for an understanding of their roles in promoting or pro-
tecting against atherosclerosis.
Indeed, when more selective approaches have been taken,
profound effects of T-cell and B-cellemediated immunity
on atherosclerosis become evident; these effects have been
summarized in many reviews, including that of Hansson
et al.22 This literature includes two reports, published in the
AJP, of studies by Elhage et al,9,24 who used several
compound mutant mice that are susceptible to hypercho-
lesterolemia and also are selectively immunodeﬁcient. In
one study, these investigators compared lesion development
in Apoe/ mice with null mutations of ab T-cell receptors
(TCRab; the type expressed by most T cells), TCRgd, CD4,
or CD8.9 Their work showed a profound reduction in
disease in the absence of all TCRab T cells; interestingly, it
also showed a signiﬁcant regional increase in disease in the
absence of just CD4þ T cells.9 In retrospect, the latter result
may reﬂect the loss of CD4þ regulatory T cells (Tregs), in
addition to effector CD4þ T cells, leading to enhanced
responses by CD8þ T cells and innate effectors. The
importance of Tregs in atherosclerosis has become apparent
from more recent studies in mouse models (reviewed by
Nilsson et al23).
In the other study, Elhage et al24 determined that the
protective effects of estradiol against fatty streak formation in
Apoe/ and Ldlr/ mice are lost in RAG-2edeﬁcient
Apoe/ and Ldlr/ mice and are restored by reconstitution
with Rag2þ/þ bone marrow. Furthermore, they showed that
Apoe/mice with selective deﬁciencies in just conventional
TCRab T cells, CD4þ T cells, CD8þ T cells, or B cells all
exhibited lesion reduction by estradiol similar to that seen in
immunocompetent Apoe/ mice.24 These studies demon-
strate the power of analysis of compound mutant mice in
evaluating the inﬂuence of different components of the
adaptive immune system on atherosclerosis, and theyThe American Journal of Pathology - ajp.amjpathol.orghighlight the presence of both lymphocyte subset-speciﬁc
effects and shared effects.Helper T-Cell Subsets and Cytokines
Since the 1980s, the known landscape of cells and mole-
cules that mediate and regulate adaptive immune responses
has steadily grown more complex. One of the emerging
complexities is the presence of multiple subsets of CD4þ T
cells. T helper type 1 cells (Th1), which produce interferon
g (IFN-g), and Th2 cells, which produce IL-4, IL-5, and
IL-13, were ﬁrst described in the 1980s,25 and more recent
work has established the existence of Th17 cells, which
produce IL-17 and IL-22.26 Each of these helper T-cell
subsets plays distinct roles in microbial defense and in
disease. Furthermore, as noted above, Tregs are a subset of
CD4þ T cells that play critical roles in preventing autoim-
munity and excessive immune responses to exogenous
antigens.27 Apoe/ and Ldlr/ mice have served as key
tools for investigating whether and how these various CD4þ
T-cellesubsets affect atherosclerosis. For example, studies
with Ldlr/ mice also carrying null mutations of the genes
encoding IL-18,28 IFN-g receptor,29 IFN-g,30 or the Th1
lineage-deﬁning transcription factor T-bet31 have shown
that Th1 responses are the major proatherogenic helper
T-cell subset in mice.29,30 These ﬁndings correlate with the
presence of IFN-g and activated CD4þ T cells in human
lesions.32,33 In contrast to Th1 cells, Tregs suppress
atherosclerotic lesion growth and inﬂammation in Apoe/
and Ldlr/ mice.23 Several articles published in the AJP
have addressed the role of T helper subsets or the cytokines
they express or depend on in the Apoe/ and Ldlr/
mouse models, including IFN-g,34 IL-4, and IL-12.35 In
another AJP article, Schulte et al36 examined the effect of
genetic bias of helper cell subset polarization on athero-
genesis. Comparing C57BL/6 Apoe/ and BALB/c Apoe/
mouse strains, they showed signiﬁcantly more lesion devel-
opment in the Th1-biased C57BL/6 background.
Cytokines may also have profound anti-inﬂammatory and
atheroprotective properties, which are indicated by accelerated
disease when the cytokines are absent. This was ﬁrst experi-
mentally demonstrated by genetic ablation of IL-10 in the
C57BL/6 model in a study by Mallat et al,37 and by reconsti-
tution of Ldlr/ mice with Il10/ bone marrow in another
study from that research group.38 Hansson and colleagues39
studied the effect of another important anti-inﬂammatory
cytokine, TGF-b, speciﬁcally on T-cellemediated inﬂamma-
tion in atherosclerosis. They showed that Apoe/ mice with
T-cellerestricted expression of a dominant negative TGF-b
receptor had markedly enhanced lesion development and
inﬂammation, compared with Apoe/ controls. In a subse-
quent study published in the AJP, Hansson and colleagues40
showed that deposition of mature collagen in lesions was
impaired in the Apoe/ mice with TGF-beresistant T cells,
suggesting that T-cellemediated inﬂammation can reduce7
Lichtmanplaque stability and enhance vulnerability to rupture. These
studies on the effects of IL-10 and TGF-b were important
stimuli for investigators to address the role of Tregs in athero-
sclerosis, because both cytokines are produced by Tregs.
T-Cell Costimulatory Molecules Affect
Atherosclerosis
Mouse models of atherosclerosis have also been key in
deﬁning roles for T-cell costimulatory molecules in proa-
therogenic immune responses. Costimulators are molecules
expressed on antigen-presenting cells in response to infection
or tissue damage and they are required, in addition to antigen
recognition, for the activation of naïve T cells to initiate T-cell
immune reactions. The best deﬁned and arguably the most
important costimulatory molecules are CD80 (B7-1) and
CD86 (B7-2), both of which are expressed on dendritic cells
and bind toCD28 onT cells. One of theﬁrst demonstrations of
the importance of costimulation in vascular pathology came
from a study of graft arterial disease in class II MHC mis-
matched cardiac transplants in mice, described in an AJP
article by Mitchell and colleagues.41 In that study, the
investigators discovered that graft arterial disease was
signiﬁcantly attenuated inCd80/ recipient mice, compared
with wild-type recipient mice. Although graft arterial disease
is not dependent on cholesterol/lipoprotein deposition, it
shares several common elements of vascular pathology with
atherosclerosis, including accumulation of intimal smooth
muscle cells; graft arterial disease can also be accelerated and
complicated by hypercholesterolemia.16 The work from
Mitchell’s research group41 served as an important stimulus
for studies of the effect of costimulatory molecule deﬁciency
in atherosclerosis using the Ldlr/ model. These studies
have shown that B7 and TNF family costimulators and their
CD28 and TNFR family receptors on T cells have profound
effects on atherosclerosis in Ldlr/ and Apoe/ mice,32 as
does the coinhibitory PD-L1/PD-1 pathway.42 Drugs target-
ing CD80 and CD86, CLTA-4, and PD-1 are approved or in
advanced clinical trials for treatment of autoimmune diseases
or cancer; therefore, it may be soon possible to assess the
effects of these target molecules in human atherosclerosis.
Conclusions
Mouse models remain centrally important to research at the
intersection of cardiovascular disease and immunology. The
approaches represented by the AJP articles reviewed here
have evolved as technology has advanced, and studies today
often include inducible and cell lineage-speciﬁc manipula-
tion of genes in a particular immune or vascular cell type.
Nonetheless, all animal models have the general limitation
that they imperfectly reﬂect human pathobiology, and this is
certainly true for mouse atherosclerosis and mouse immu-
nopathology. One important example is the fact that the
mouse models do not adequately recapitulate the human8vulnerable plaque and plaque rupture, but there is abundant
circumstantial evidence that inﬂammation and adaptive
immune responses contribute to these processes. The
greatest challenge is to identify the ﬁndings from mouse
studies that are most relevant to human disease, and to move
to truly translational studies that can lead to more effective
therapies. Given the record of excellence of the AJP in
reporting advances in the study of human disease, we can
look forward to reading in this journal about new important
results of human cardiovascular immunology research.
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